Product information and disease description Product description Product information Dosing and administration

Dosage

4 evidence topics · 4 sources

Summary: phase 3 dosing regimen

In LUGANO and LUCIA, all participants received scheduled aflibercept 2 mg from day 1 through week 8. Participants randomized to vorolanib intravitreal insert received 2.7 mg (two inserts in a single injection) at week 8 and were redosed every 6 months (every 24 weeks), with the second dose at week 32 and the third planned dose at week 56, for a total of four doses over the 2-year trials. Supplemental aflibercept was permitted in both arms when protocol criteria were met.

Phase 3: dose and redosing interval

“Patients in the DURAVYU treatment arm will receive an intravitreal injection of DURAVYU every six months, starting at month two of the trial with a total of four injections over the two-year trial.” (opens the source at this quote in a new tab)

“DURAVYU dosing every 6 months (q24W)” (opens the source at this quote in a new tab)
“the number of injections includes the DURAVYU injections at Week 8 and Week 32, and all supplemental injections after Week 8 through Week 56” (opens the source at this quote in a new tab)

Phase 3: second and third doses

“As of May 2, 2026, all active patients in the treatment arm have reached the Week 32 visit, during which patients received their second DURAVYU dose. Over 35% of those patients have also received their third planned dose at Week 56.” (opens the source at this quote in a new tab)

Dose modification

“Dose modification is not applicable since EYP-1901 and aflibercept are for single-delivery only.” (opens the source at this quote in a new tab)